ArticleTherapeutic advances in gastroenterology2014
Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: a double-blind placebo-controlled randomized clinical trial.
Article in Therapeutic advances in gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05701683 (IMPROVEMENT in ERADICATION of H-PYLORI INFECTION With ADDITION of LACTOBACILLUS REUTERI), which is not on this map. Cited by 38 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
IMPROVEMENT in ERADICATION of H-PYLORI INFECTION With ADDITION of LACTOBACILLUS REUTERI
Who cites it
38 citing papers in PubMed, 5 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- Efficacy and safety of probiotics combined with bismuth-containing quadruple therapy forFrontiers in microbiology · 2025Pooled it
- Role of probiotic as adjuvant in treating various infections: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis.Medicine · 2019Pooled it
- Efficacy of Lactobacillus-supplemented triple therapy for H. pylori eradication: A meta-analysis of randomized controlled trials.PloS one · 2019Pooled it
- Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy.World journal of gastroenterology · 2014Pooled it
- Efficacy and Safety of Postbiotic Contained Inactivated Lactobacillus reuteri ( Limosilactobacillus reuteri ) DSM 17648 as Adjuvant Therapy in the Eradication of Helicobacter pylori in Adults With Functional Dyspepsia: A Randomized Double-Blind Placebo-Controlled Trial.Clinical and translational gastroenterology · 2024Trial
- Trial
- Trial
- A Randomised, Controlled Trial: Effect of a Multi-Strain Fermented Milk on the Gut Microbiota Recovery afterNutrients · 2021Trial
- Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study.Probiotics and antimicrobial proteins · 2015Trial
- Gastric Microbiota Dysbiosis and Microbiome-Based Interventions in Chronic Atrophic Gastritis.Nutrients · 2026Review
- Research Progress on the Role ofBiology · 2026Review
- Efficacy and safety of Qingwei Zhitong pellets-containing quadruple therapy for eradication: a prospective, single-center, randomized trial.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Screening Probiotics for Anti-Foods (Basel, Switzerland) · 2024Article
- Article
- Real-World Situation of Eradication Regimens and Risk Factors forClinical and experimental gastroenterology · 2024Article
- Lacticaseibacillus casei T1 attenuates Helicobacter pylori-induced inflammation and gut microbiota disorders in mice.BMC microbiology · 2023Article
- Efficacy and safety ofFrontiers in gastroenterology (Lausanne, Switzerland) · 2023Article
- Comparative effectiveness of different probiotics supplements for triple helicobacter pylori eradication: a network meta-analysis.Frontiers in cellular and infection microbiology · 2023Review
- Role of probiotics in managing various human diseases, from oral pathology to cancer and gastrointestinal diseases.Frontiers in microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe eradication rate of Helicobacter pylori following the standard triple therapy is declining. This study was conducted to test whether the addition of Lactobacillus reuteri to the standard triple therapy improves the eradication rates as well as the clinical and pathological aspects in H. pylori infection.
methodsA total of 70 treatment-naïve patients were randomly assigned into group A (the L. reuteri treated group) and group B (the placebo control group). Patients were treated by the standard triple therapy for 2 weeks and either L. reuteri or placebo for 4 weeks. They were examined by symptom questionnaire, H. pylori antigen in stool, upper endoscopy with biopsies for rapid urease test and histopathological examination before treatment and 4 weeks after treatment.
resultsThe eradication rate of H. pylori infection was 74.3% and 65.7% for both L. reuteri and placebo treated groups, respectively. There was a significant difference regarding the reported side effects, where patients treated with L. reuteri reported less diarrhea and taste disorders than placebo group. A significant difference within each group was observed after treatment regarding Gastrointestinal Symptom Rating Scale (GSRS) scores; patients treated with L. reuteri showed more improvement of gastrointestinal symptoms than the placebo treated group. The severity and activity of H. pylori associated gastritis were reduced after 4 weeks of therapy in both groups. The L. reuteri treated group showed significant improvement compared with the placebo treated group.
conclusionTriple therapy of H. pylori supplemented with L. reuteri increased eradication rate by 8.6%, improved the GSRS score, reduced the reported side effects and improved the histological features of H. pylori infection when compared with placebo-supplemented triple therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.